

TAIHO PHARMACEUTICAL AND PHOST'IN THERAPEUTICS ANNOUNCE AN OPTION AND LICENSE AGREEMENT ON THE FIRST-IN-CLASS GNT-V INHIBITOR PHOX430

Tokyo (Japan) and Montpellier (France), August 2023, the 25th

Taiho Pharmaceutical Co., Ltd. (Taiho Pharmaceutical) and Phost'in Therapeutics SAS (Phost'in) today announced that the two companies have entered into an option and license agreement through which Taiho Pharmaceutical will obtain option rights to in-license PhOx430, a First-in-Class small molecule targeting GnT-V (N-acetylglucosaminyltransferase-V).

According to the terms of this agreement, Taiho Pharmaceutical will make an upfront payment to Phost'in. In return, Taiho Pharmaceutical will receive an option right to in-license PhOx430 and additional undisclosed compounds and to exclusively develop and commercialize the compounds in Japan and certain other territories in Asia (excluding China). When Taiho Pharmaceutical will exercise its option right, the company will make an option exercise payment, as well as additional payments upon achievement of clinical, regulatory and commercial milestones. The company will also pay royalties on net sales in its regions.

Phost'in retains the right to develop and commercialize the licensed compounds in other territories, including North America, Europe and China and will be in charge of manufacturing.

"We believe in the potential of Phost'in Therapeutics's cutting-edge technologies targeting N-glycosylation to bring benefit to the patients in the oncology and fibrosis areas. This agreement resonates with our vision of supporting innovative and highly valuable new drugs to accelerate R&D for significant unmet needs," said **Atsushi Azuma, Managing Director at Taiho Pharmaceutical.**

Karine Chorro, CEO of Phost'in Therapeutics, remarked *"We are very pleased to announce this collaboration with Taiho Pharmaceutical, a leading pharmaceutical company in the oncology area. This demonstrates the value of our targeted first-in-class, small molecule Gnt-V inhibitor approach to the treatment of solid tumours in cancer. We are eager to continue developing this novel approach in collaboration with our new partner".*

About PhOx430

PhOx430 is a First-in-Class N-glycosylation inhibitor, designed to target GnT-V, a key n-glycosylation enzyme responsible for suppressing the immune response and supporting cancer proliferation as well as formation of fibrotic tissues. PhOx430 is currently evaluated in Europe in a Phase I/II in patients with advanced solid tumors (the PhAST trial). It is also the first program from the Phost'Screen™ platform that combines unique and patented chemical libraries with cutting-edge screening tools to produce selective n-glycosylation inhibitors for the treatment of cancer and other serious immunoinflammatory diseases.

About Taiho Pharmaceutical

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., is an R&D-driven specialty pharma company with a focus on oncology. Taiho Pharmaceutical also has development programs in allergy and immunology, and consumer healthcare products. Our corporate philosophy the form of a pledge: "We strive to improve human health and contribute to a society enriched by smiles."

For more information about Taiho Pharmaceutical, please visit: <https://www.taiho.co.jp/en/>

About Phost'in Therapeutics

Phost'in Therapeutics is a biotechnology company specialized in the discovery and development of NCE's specifically targeting abnormal pathogenic glycosylation mechanisms. In addition to PhOx430 clinical development, the company leads upstream research programs in several other diseases using its unique expertise and discovery platform. A spin-off of the academic world, Phost'in possesses, in addition to its own patents, an exclusive license for two families of academic patents owned by CNRS (Centre National de la Recherche Scientifique), ENSCM (Ecole Nationale Supérieure de Chimie de Montpellier), and the Universities of Montpellier, Sorbonne Paris Nord and Paris Saclay. Based in Montpellier, France, the company was awarded a national Special Prize in the 2014 ILab competition of the French Research Ministry at its creation and has since received the renewed support of bpifrance, LifeScience cluster Eurobiomed, Region Occitanie and Montpellier Med Vallée.

For more information about Phost'in Therapeutics, please visit: www.phostin.com

Or contact:

(Worldwide) Richard Meadows, CBO, richard.meadows@phostin.com

(FR/EU) Karine Chorro, CEO, contact@phostin.com

Phost'in Therapeutics, 104 rue de la Galera, 34 090 Montpellier France

Phost'in was assisted by MCE CARREL, Alexandra Carrel and Mathilde Salavin, in the negotiation of this agreement.